Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308763 · ClinicalTrials.gov registry record · NA
Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals
A NA study, sponsored by University of Tennessee.
- Completed
- Registry status
- NA
- Development phase
- 594
- Enrollment target
NCT00308763: Completed NA study, sponsored by University of Tennessee.
NCT00308763 is a NA study that has completed, run by University of Tennessee. The registered enrollment target is 594 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00308763, a NA study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- NA
- Development phase
- 594 participants
- Enrollment target
Study Summary
Nicotine addiction is a serious health problem in the United States; 46 million people smoke cigarettes, and 70% of those are trying to quit. The nicotine patch and bupropion, a medication used to reduce nicotine cravings, are two commonly used smoking cessation aids. Both have been shown to reduce smoking rates, however, the effectiveness of combining the two treatments has not been widely examined. This study will evaluate the effectiveness of the nicotine patch combined with bupropion at reducing smoking rates among younger, low-income, and minority individuals.
Interventions
- DRUG Nicotine Patch
- DRUG Sustained Release Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2004-01 |
| Est. Completion | 2008-12 |
| Phase | NA |
What the finished NCT00308763 record still lists
NCT00308763 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which Nicotine Patch is the first listed.
NCT00308763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00308763 about?
NCT00308763 is a clinical study titled "Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals". Nicotine addiction is a serious health problem in the United States; 46 million people smoke cigarettes, and 70% of those are trying to quit. The nicotine patch and bupropion, a medication used to reduce nicotine cravings, are two commonly used smoking cessation aids. Both have been shown to reduce ...
What is the current status of trial NCT00308763?
This trial is currently completed. It is a NA study. The enrollment target is 594 participants. The study started on 2004-01. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00308763?
The interventions under investigation include: Nicotine Patch (DRUG), Sustained Release Bupropion (DRUG).
Who is sponsoring clinical trial NCT00308763?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00308763's enrollment target sits among peer trials
594 174th of 2000 higher than 1,826 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia